News | March 01, 2023
AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
This artificial RNA ligase has higher thermostability than natural RNA ligase
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
There is a fast resurgence in the transplant activities post COVID
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Subscribe To Our Newsletter & Stay Updated
